Holiday closures split the tape.

Friday breadth held; Monday risk is cross-asset

At Friday's close, 311 U.S. names advanced against 177 decliners while the S&P 500 gained 0.59%. Real Estate (+1.86%) and Health Care (+1.58%) led, but Communication Services fell 1.51% as the SpaceX spectrum deal punished carriers and re-rated tower owners.

Monday's modestly higher U.S. futures arrive against a rougher Asian close: Shanghai fell 0.43% and KOSPI lost 3.65%. That makes Wednesday CPI and the bank-earnings cycle the next tests of Friday's broad rebound. The week in one line: if Wednesday's CPI runs hot, the financing queue behind the AI buildout gets more expensive and the bank rally gets tested; if it cools, Friday's rebound gets its second wind.

Friday's towers-versus-carriers rotation was the session's loudest repricing: Crown Castle +15.6%, American Tower +9.3%, SBA Communications +7.3% against T-Mobile -13.3%, AT&T -9.8%, Verizon -8.8%. The trigger is SpaceX's roughly $8 billion purchase of 800 MHz spectrum — airwaves Grain Management had bought from T-Mobile itself in August for $2.9 billion cash plus 600 MHz licenses, then flipped to SpaceX for nearly three times the cash price. Bernstein's read: the purchase keeps 'the terrestrial network build option very much alive' — SpaceX says Starlink Mobile could become 'a major mobile carrier in the US,' with a full network buildout estimated at $50-130 billion. FCC approval is still pending, and T-Mobile's steepest drop since its 2013 listing partly reflected ex-dividend timing. The question for investors: real low-band competitor or sentiment trade? Bernstein's $50-130 billion buildout number is the anchor — the threat is priced on ambition; what's real today is the optionality. The towers collect rent either way.

Meanwhile SpaceX is raising capital on a second front. Bloomberg reported October 6 that the company is in early-stage talks — which could still end with no deal — to raise about $40 billion (~$10 billion in bank loans plus ~$30 billion in investment-grade debt) to buy Nvidia chips, with Apollo Global Management leading a financing expected to close in 2027 (by Laura Benitez and Carmen Arroyo; the one subscriber article in this edition). The context is the AI-buildout financing queue: global investment-grade plus high-yield AI-infrastructure bond issuance already stands at ≥$360 billion year-to-date — 5.8% of global bond sales versus 1.9% last year. Apollo sits inside Nvidia's August coalition (with Blackstone, BlackRock, Brookfield, Goldman Sachs and KKR) that pledged to 'create dedicated pools of capital at significant scale at attractive rates for Nvidia customers.' Wednesday's CPI print decides how expensive that queue gets.

Moderna's +14.2% day was the session's other big re-rating, and the NIH headline carries more detail than the catalyst line. The effort has a name — the Therapeutic Cancer Vaccines Initiative (TCVI), a roughly $200 million national public-private program run through the Foundation for the NIH — targeting pancreatic, liver and colorectal cancers plus a subset of pediatric tumors, launching in December (via alphapilot.tech/Benzinga). NCI Director Dr. Anthony Letai and FNIH's Stacey Adam are the architects; the stated goal is a cancer vaccine available in a doctor's office within 7-10 years, against the 8-15 years a fragmented process takes. Moderna's claim on the agenda is the furthest advanced in the field: intismeran autogene (V940), its mRNA therapy paired with Merck's Keytruda, is the only cancer-vaccine program with definitive late-stage results — the Phase 3 INTERPATH-001 trial in 1,137 patients with advanced melanoma delayed both recurrence and spread (August 2026), with full data due later this month. Two honest caveats: the NIH program is still in planning and Moderna has disclosed no contracts or funding under it (gate.com); and the push follows HHS's August 2025 decision to end BARDA mRNA funding — 22 contracts canceled — which makes a $200 million NIH cancer-vaccine moonshot a sharp policy turn (beckershospitalreview.com).

Humana's +11.6% was the market repricing a $3 billion promise. TD Cowen's Ryan Langston estimates the star-ratings turnaround could net Humana $3 billion or more in extra revenue in 2028 — the year these ratings set bonus payments — after the company got its largest contract (about 2.4 million members) back above the 4-star cutoff (healthcaredive.com). The trajectory: from ~20% of members in 4+ star plans for 2026 to 95% for 2027, with six contracts at 4.5 stars covering 42% of members; Humana's enrollment-weighted average is about 4.18 against an industry 3.99. And it did this in a year when only 37% of Medicare Advantage contracts hit four stars, down from 44.4% (CMS via kffhealthnews.org) — JPMorgan had sized the turnaround at just 60-70%. The check on the excitement: the extra cash doesn't arrive until 2028, and the annual enrollment period (October 15-December 7) is where members vote with their feet.

Two analyst-driven moves round out the tape. Datadog's +7.1% to a record $293.26 came after CIBC's Todd Coupland lifted his target to $315 from $280 (Outperform), arguing consensus growth estimates — 29% in Q3, slowing to 26% in Q4 — look beatable after five straight quarters of accelerating revenue (tickerspark.ai). Q2 revenue was $1.12 billion, up 35.6% year over year; FBN Securities separately initiated at Outperform with a $325 target. The next test is early-November earnings, where investors will watch whether the largest-AI-customer usage step-down disclosed in Q2 has stabilized. HP's -6.9% was the mirror image: Evercore ISI cut it to In Line on tariff pull-forward demand risk — sales borrowed from next year — with the company's own filing assuming a mid-single-digit percentage decline in 2027 global PC units plus memory/storage cost inflation. Same week, same tests for both: bank earnings, CPI, and whether the AI spend keeps accelerating.

For the working week: if you buy hardware, the tariff pull-forward story says negotiate now — HP's filing assumes 2027 PC demand shrinks mid-single-digits, and vendors know it. If you manage benefits, the Medicare Advantage open-enrollment window (October 15-December 7) just got interesting: Humana's 4.5-star plans carry richer supplemental benefits funded by the bonuses. And if you touch corporate budgets, watch Wednesday's CPI through the services line (3.0% in August): that's the number that decides whether your company's borrowing costs fall this winter. And if markets aren't your day job: the number to carry into any conversation this week is $118 versus $100 — the market's live price tag for a closed Hormuz versus a dangerous-but-open one.